文献速递癫痫

癫痫基因检测的诊断率与成本效益:荟萃分析与成本效益研究

Diagnostic yield of genetic tests in epilepsy: A meta-analysis and cost-effectiveness study.
PubMed 文献 · Neurology · 2019-01-28

该研究通过荟萃分析和成本效益模型,比较了染色体微阵列(CMA)、癫痫基因面板(EP)和全外显子组测序(WES)在病因不明癫痫患者中的诊断率和成本效益。WES诊断率最高(0.45),EP次之(0.23),CMA最低(0.08);WES最具成本效益,但校正发表偏倚后EP更具成本效益;CMA作为一线检测从成本效益角度不被支持。

要点

  • WES诊断率最高(0.45),EP次之(0.23),CMA最低(0.08)。
  • WES最具成本效益(ICER $15,000/诊断),校正发表偏倚后EP更优(ICER $15,848/诊断)。
  • 对不明原因癫痫患者,建议从WES或EP开始检测,CMA不宜作为一线。

核心结论

  • WES和EP是癫痫最具成本效益的基因检测,支持在广泛的不明原因癫痫患者中从这些检测开始。
  • CMA虽较便宜但诊断率低,从成本效益角度不支持其作为一线检测。

研究设计与样本

  • 本研究为荟萃分析和成本效益研究,比较了涉及CMA、EP和WES三种基因检测的策略,以「无基因检测」作为对照。

主要发现

  • WES诊断率最高:0.45(95%CI 0.33-0.57),校正潜在发表偏倚后为0.32(95%CI 0.22-0.44)。
  • EP诊断率为0.23(95%CI 0.18-0.29),CMA诊断率为0.08(95%CI 0.06-0.12)。
  • 最具成本效益的单项检测为WES(ICER $15,000/诊断),但校正发表偏倚后为EP(ICER $15,848/诊断)优于WES(ICER $34,500/诊断)。
  • 在联合策略中,最具成本效益的是WES后若未诊断行EP再行CMA(ICER $15,336/诊断),校正发表偏倚后为EP±CMA±WES(ICER $18,385/诊断)。
  • 单项检测和检测策略的成本效益存在重叠,但CMA始终不如WES和EP具成本效益。

关键数值与推荐

  • WES诊断率0.45(95%CI 0.33-0.57),校正发表偏倚后0.32(95%CI 0.22-0.44)。
  • EP诊断率0.23(95%CI 0.18-0.29)。
  • CMA诊断率0.08(95%CI 0.06-0.12)。
  • WES的ICER为$15,000/诊断;校正发表偏倚后EP的ICER为$15,848/诊断,WES为$34,500/诊断。
  • 联合策略WES→EP→CMA的ICER为$15,336/诊断;校正发表偏倚后EP±CMA±WES的ICER为$18,385/诊断。

临床怎么用

  • 对于广泛的不明原因癫痫患者,可首先考虑WES或EP进行基因检测。
  • 从成本效益角度,不建议将CMA作为一线基因检测。

局限性

  • 成本效益结果受潜在发表偏倚影响,校正后最优检测和策略发生变化。
  • 单项检测与联合策略的成本效益存在重叠,结论需结合具体临床情景解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the cost-effectiveness of genetic testing strategies in patients with epilepsy of unknown etiology. METHODS: This meta-analysis and cost-effectiveness study compared strategies involving 3 genetic tests: chromosomal microarray (CMA), epilepsy panel (EP) with deletion/duplication testing, and whole-exome sequencing (WES) in a cost-effectiveness model, using "no genetic testing" as a point of comparison. RESULTS: Twenty studies provided information on the diagnostic yield of CMA (8 studies), EP (9 studies), and WES (6 studies). The diagnostic yield was highest for WES: 0.45 (95% confidence interval [CI]: 0.33-0.57) (0.32 [95% CI: 0.22-0.44] adjusting for potential publication bias), followed by EP: 0.23 (95% CI: 0.18-0.29), and CMA: 0.08 (95% CI: 0.06-0.12). The most cost-effective test was WES with an incremental cost-effectiveness ratio (ICER) of $15,000/diagnosis. However, after adjusting for potential publication bias, the most cost-effective test was EP (ICER: $15,848/diagnosis) followed by WES (ICER: $34,500/diagnosis). Among combination strategies, the most cost-effective strategy was WES, then if nondiagnostic, EP, then if nondiagnostic, CMA (ICER: $15,336/diagnosis), although adjusting for potential publication bias, the most cost-effective strategy was EP ± CMA ± WES (ICER: $18,385/diagnosis). While the cost-effectiveness of individual tests and testing strategies overlapped, CMA was consistently less cost-effective than WES and EP. CONCLUSION: WES and EP are the most cost-effective genetic tests for epilepsy. Our analyses support, for a broad population of patients with unexplained epilepsy, starting with these tests. Although less expensive, CMA has lower yield, and its use as the first-tier test is thus not supported from a cost-effectiveness perspective.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sánchez Fernández I, Loddenkemper T, Gaínza-Lein M, et al. Diagnostic yield of genetic tests in epilepsy: A meta-analysis and cost-effectiveness study. Neurology. 2019. PMID: 30610098. doi:10.1212/WNL.0000000000006850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。